November 05, 2015
Wellesley, Mass., November 05, 2015 – The single-cell analysis market is still in its early stages of growth and penetration into multiple market segments, providing excellent opportunities for companies to offer innovative solutions. BCC Research reveals in its new report that some trends in single-cell analysis include integration and automation single-cell workflow, and combining CTC and cfDNA analysis in a single system.
Single-cell analysis is a disruptive technology that enables analysis of single cells out of a complex mixture of cells. This type of analysis is key to understanding complex systems in fields as diverse as neurology, stem cell biology and cancer.
The global single-cell analysis market is projected to reach $626.2 million and $1.6 billion in 2015 and 2020, respectively, reflecting a five-year compound annual growth rate (CAGR) of 20.7%. As an industry end-user, the research, drug development and applied segment is expected to reach $386.1 million and $808.5 million in 2015 and 2020, respectively, with a five-year CAGR of 15.9%. The fastest growing industry end-user is the diagnostics segment, which should reach $796.8 million in 2020, up from an anticipated $240.1 million in 2015, thanks to a five-year CAGR of 27.1%.
Single-cell analysis tools are penetrating these market segments at a high rate due to both improvements in workflow integration and automation, and to the ability to analyze heterogeneous cell populations in fields as diverse as immunology, neurology, stem cell biology, oncology and basic cell biology.
Within the diagnostics market, cancer applications dominate this market, with the need to understand and characterize single cells within heterogeneous tumors helping to drive adoption. In particular, the liquid biopsy market segment is growing at a fast rate, driven by the need for noninvasive and repeated testing over the course of therapy or for monitoring to help guide oncologists.
Technology challenges in single-cell analysis arise from the small sample sizes available and the low concentration of the cell of interest versus background cells. These challenges necessitate innovations in analysis methods including amplification methods and noise reduction. For example, Fluidigm is developing an automated, integrated system for single-cell analysis. Called Polaris, the system will combine the capture and isolation of individual cells with their sample preparation and subsequent analysis of their gene expression.
“Further to the integration trend, combination of CTC and cfDNA analysis in a single system is being pursued. Cynvenio, for example, markets a platform that combines isolation and analysis of CTCs with analysis of the germline and somatic mutations in circulating cell-free DNA (cfDNA),” says BCC Research analyst John Bergin. “The advantage of doing this is the ability to confirm that a reported mutation is real, and is not noise or a spurious signal.”
Single-Cell Genomics and Proteomics: Emerging Technologies and Markets (BIO143A) examines emerging technologies such as cell isolation, sample preparation and next generation sequencing. The report identifies market dynamics, growth drivers, inhibitors, opportunities, and forecasts trends and revenue through 2020.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at firstname.lastname@example.org.
Single-Cell Genomics and Proteomics: Emerging Technologies and Markets( BIO143A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.